A New Player Just Entered the Weight-Loss Drug Race

While the headlines were still processing Eli Lilly's retatrutide results, a different drug combination released its own Phase 3 data.

CagriSema, a combination of semaglutide (already FDA-approved for weight loss as Wegovy) and cagrilintide (still under investigation), produced an average 20.4% body weight reduction over 68 weeks in a major clinical trial. Among participants who completed the full treatment course, that number climbed to 22.7%.

The placebo group saw 3% weight loss. That's a 17.3 percentage-point gap — statistically significant at P < 0.001.

The Trial Details Matter

This wasn't a small study. According to UAB News, more than 3,400 adults participated. All were obese or overweight with at least one related health complication but did NOT have diabetes. Everyone also received lifestyle counseling.

The trial was led by W. Timothy Garvey, M.D. of the University of Alabama at Birmingham and published in the New England Journal of Medicine on June 26, 2025.

Cagrilintide is a long-acting synthetic form of amylin — a hormone normally secreted alongside insulin from the pancreas. This marks the first time cagrilintide has been tested in a Phase 3 trial.

What About Side Effects?

Gastrointestinal issues — nausea, vomiting, constipation — showed up at rates comparable to semaglutide alone, according to UAB News. Most were mild to moderate and temporary.

This mirrors the GI profile that the entire GLP-1 drug class has carried since Ozempic became widely discussed. It's a known trade-off patients encounter.

Long-term cardiovascular safety data is still pending. Garvey's team acknowledged further research is needed.

The Retatrutide Number That Changes Everything

The Washington Post reported that Eli Lilly's retatrutide, at its highest dose, helped patients shed more than 30% of their body weight — putting it in the same range as gastric bypass surgery.

We already reported on retatrutide's Phase 3 wins. The 30%+ figure at peak dosing is now being discussed in direct comparison to bariatric surgery outcomes.

What Mainstream Coverage Is Missing

The Washington Post ran much of this as opinion pieces — twice, with near-identical framing. The reporting gap is significant.

First, the cost and access problem barely registers in coverage. Semaglutide (Wegovy) runs roughly $1,300 per month before insurance. CagriSema combines semaglutide with an additional investigational compound. What does that cost at scale?

Second, J.P. Morgan's 2026 supply-and-demand analysis on weight-loss drugs flags a constraint the media hasn't covered seriously: manufacturing capacity. Demand for these drugs is outpacing production. Phase 3 wins require drugs that patients can actually obtain.

Third, the long-term data gap remains. Both retatrutide and CagriSema show impressive 68-week results. What happens at five years? Early semaglutide data indicates weight returns largely after patients stop treatment. These are worth examining.

The Bigger Picture: Obesity Is a $200 Billion Problem

Over 40% of American adults are obese, according to the CDC. Downstream costs — heart disease, type 2 diabetes, cancer — run into the hundreds of billions annually in healthcare spending.

If CagriSema and retatrutide both clear full FDA approval, and if the supply chain keeps pace, and if insurers actually cover them, that represents a massive shift in American healthcare.

What Comes Next

CagriSema is real, the trial is rigorous, and 20%+ weight loss in a 3,400-person study published in the New England Journal of Medicine warrants serious attention. Retatrutide is reportedly hitting 30%+ at high doses. The science is advancing.

The access problem, the cost structure, and the long-term safety questions remain unresolved.